Ensoma debuts with $70M, Takeda deal to pursue off-the-shelf genomic medicines

From therapies that replace disease-causing genes with normal ones to CRISPR-based treatments that edit genes inside the body, the biotech industry has made tremendous strides in genomic medicine. Despite these advances, today’s approaches still have requirements that limit their accessibility. Ensoma hopes to change that with a suite of off-the-shelf genomic medicines.

The company launches with $70 million in venture financing as well as a partnership with Takeda that could net it up to $100 million in the near term.